Lineage Cell Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two in USD from Q2 2019 to Q2 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Lineage Cell Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two history and growth rate from Q2 2019 to Q2 2022.
  • Lineage Cell Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Two for the quarter ending June 30, 2022 was $508K.
Lessee, Operating Lease, Liability, to be Paid, Year Two, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q2 2022 $508K Jun 30, 2022 10-Q 2022-08-11
Q3 2019 $1.59M Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $1.46M Jun 30, 2019 10-Q 2019-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.